Chronic Pain And Levodopa Therapy in Parkinson’s Disease Patients
Carlos Henrique Ferreira Camargo1, *, Marcelo Rezende Young Blood2, Camila Medyk2, Matheus Gomes Ferreira3, Marcelo Machado Ferro4, Hélio Afonso Ghizoni Teive1, 3
Identifiers and Pagination:Year: 2022
E-location ID: e1874205X2209260
Publisher ID: e1874205X2209260
Article History:Received Date: 6/6/2022
Revision Received Date: 3/8/2022
Acceptance Date: 29/8/2022
Electronic publication date: 15/12/2022
Collection year: 2022
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pain is a frequent non-motor symptom in patients with Parkinson’s disease (PD) and appears to be related to low levels of dopamine. This study describes the characteristics of chronic pain in a group of PD patients undergoing levodopa therapy.
This was a cross-sectional study. The pain was assessed in 21 selected PD patients with chronic pain using several scales and instruments. Changes in pain response from levodopa use (wearing-off phenomenon) were monitored.
The most prevalent type of pain was nociceptive (71.4%), musculoskeletal and dystonic, but neuropathic pain accounted for the highest pain score according to the Parkinson’s Disease Pain Classification System (45.5±30.08). Patients with neuropathic, nociplastic, or nociceptive pain upon wearing-off were those who responded to levodopa (p=0.999). According to the McGill questionnaire, patients with pain upon wearing-off had higher scores in the affective/motivational dimension (p=0.022).
Using a new pain classification and scoring tool, this study corroborates a good response to levodopa in PD-related pain.